Douglas Arnold, M.D., FRCP(C)
Douglas L. Arnold, MD, James McGill Professor of Neurology & Neurosurgery at the Montreal Neurological Institute of McGill University, directs a research laboratory that uses advanced MRI acquisition and analysis techniques to improve the understanding of how brain injury and repair in MS evolve and how therapeutic interventions can influence this. He also directs a company that provides advanced MRI analysis services for drug development.
Scott R. Burger, M.D.
Dr. Burger is the principal of Advanced Cell & Gene Therapy LLC, a consulting firm specializing in cell, gene, and tissue-based therapies. Dr. Burger received his M.D. from the University Of Pennsylvania School Of Medicine, and completed postgraduate training in Laboratory Medicine, as well as a clinical fellowship in Transfusion Medicine and a postdoctoral research fellowship, at Washington University in St. Louis. Dr. Burger served as medical director of the Cell Therapy Clinical Laboratory and Molecular and Cellular Therapeutics Facility at University of Minnesota. There he was responsible for process development, validation, and GMP production of a broad range of novel cell and gene therapies, including blood- and bone marrow-derived stem cells, umbilical cord blood cells, dendritic cell vaccines, activated natural killer cells, lymphocyte-based gene therapies, and mesenchymal stem cells, in support of 75 clinical trials.
Dr. Burger also was vice-president for Research and Development at Merix Bioscience, a biotechnology company focused on dendritic cell immunotherapy. He serves on the scientific advisory boards of several cell therapy biotechnology companies, the editorial boards of the journals BioProcessing and Cytotherapy, the Gene Therapy, Legal/Regulatory Affairs, and Executive committees of the International Society for Cellular Therapy, the Cellular Therapy Standards Program Unit of the American Association of Blood Banks, and is editor of the ISCT Telegraft.
A frequently invited speaker at industry and academic conferences, he is the author or coauthor of more than 100 scientific publications and presentations at scientific meetings, and recipient of numerous honors and awards. As a consultant in cell and gene therapies, Dr. Burger works with clients in industry and academic centers worldwide, providing assistance in process development and validation, GMP/GTP production, GMP facility design and operation, regulatory issues, and strategic analysis.
Patricia K. Coyle, M.D.
Dr. Coyle is a Professor of Neurology and Director of the Multiple Sclerosis Comprehensive Care Center at Stony Brook University Hospital. She received her BS with highest honors from Fordham University, and her MD from Johns Hopkins, where she was elected to Alpha Omega Alpha. She then completed a Neurology residency/Chief resident, followed by a Fellowship in Neuroimmunology and Virology, all at Johns Hopkins.
Dr. Coyle is an expert in neurologic infectious disease, in particular Lyme Disease and Multiple Sclerosis. She is a Director of the American Board of Psychiatry and Neurology, holds leadership positions in the American Academy of Neurology and American Neurologic Association, and lectures widely to national/international audiences. Additionally, she has served as an expert adviser to the Food and Drug Administration while maintaining her research laboratory serving as the basis for her clinical and research practice. Her research is funded by the NIH and she is involved in a number of therapeutic trials testing new agents for Multiple Sclerosis. Dr. Coyle has authored numerous publications in these areas.
Edward J. Fox, M.D., Ph.D.
Dr. Fox is the director of the Multiple Sclerosis Clinic of Central Texas in Austin and Round Rock, Texas. After receiving a Bachelors Degree at Washington University in St. Louis, he completed the Medical Scientist Training Program for his M.D., Ph.D. and his Neurology residency at Baylor College of Medicine in Houston. His Ph.D. in Immunology was awarded for the thesis "Growth Requirements of Human Suppressor T Lymphocytes." As Chief Resident, he received the Outstanding Academic Resident Award.
Since starting practice in the Austin area in 1992, he has been involved in numerous MS research protocols and has spoken internationally on topics related to Neuroimmunology. He is also on the advisory committee for the Lone Star Chapter of the National Multiple Sclerosis Society, and is a member of the Consortium of Multiple Sclerosis Centers. In association with the NMSS and St. David's Hospital System, he has opened a comprehensive MS rehabilitation program in Austin. In 2003, the Lone Star Chapter of the National Multiple Sclerosis Society awarded him the Volunteer of the Year Award, Medical Division, and entry into the Volunteer Hall of Fame. Dr. Fox has been appointed Clinical Assistant Professor of Neurology for the University of Texas Medical Branch and is leading student and resident training in neuroimmunology and the role of clinical research in private practice.
Brian D. Loftus, M.D.
Dr. Loftus did his medical school training and his Neurology Residency at the Baylor College of Medicine. While in medical school, he received the Outstanding Student in Neurology award for his graduating class.
After neurology training, Dr. Loftus joined Diagnostic Clinic of Houston, a multispecialty physician group in the Texas Medical Center. He began doing Neurology Research at Diagnostic Clinic and has been Diagnostic Clinic's principal investigator on several studies. To date these studies have focused on migraines, diabetic neuropathy, post-herpetic neuralgia, and the prevention of stroke. Research funding has been provided by Astra-Zeneca, Glaxo, and Johnson and Johnson.
Dr. Loftus has been an invited speaker for the Texas Association of Family Practice 2001 CME meeting and again in 2004. In 2003, he spoke for the Texas Neurological Association's Annual Meeting. He is a member of the American Academy of Neurology, American Medical Association, Texas Neurological Association, Texas Medical Association, and the Harris County Medical Association.
Dr. Loftus believes strongly in the tradition of physicians educating their own. From medical students, to residents, to other specialists and contemporaries, Dr. Loftus loves to teach. For ten years, as Voluntary Associate Professor of Baylor College of Medicine, Department of Neurology, he spent part of each day for one month (including weekends) a year as the Neurology Inpatient and Consult Attending at Ben Taub General Hospital. During this month, he is responsible for directing the neurology residents and medical students for all inpatient neurology patients. He current gives numerous educational talks each year to physicians on migraine, epilepsy, and neuropathic pain.
Dr. Loftus admits his private practice patients to either the Methodist Hospital, where he is on active staff or Park Plaza Hospital. He has served on a Quality Assurance Board of a medical hospital for 10 years.
Mathilda Mandel, M.D.
Dr. Mandel is the l Director of the Blood bank and Transfusion Center at Sheba Medical Center, Israel, since 1994. Completed her M.D. studies in 1981 at the Sackler School of Medicine and won her M.H.A (Master's Degree in Health Management) in 2000 at Leon Recanaty Faculty of Management, Tel-Aviv University.
Dr. Mandel is a specialist in Pediatrics, General Hematology and Pediatric Hemato-Oncology. Served as chairman of the Division of Laboratories between 2000 -2003 and acts as Head of Bid and Tender committee since 2002.
Dr. Mandel's main research interests are related to immune mechanisms in autoimmunity and cancer. She is part of a group that studies autoimmunity gene expression signatures in peripheral blood mononuclear cells using advanced microarray technology. She is involved in clinical studies and basic research evaluating the therapeutic effects of T-cell vaccination using autologous T- cell lines generated from MS patients and expanded in the TCV laboratory of the Blood Center and used for vaccination at the Multiple Sclerosis Center.
Dawn McGuire, M.D.
Dawn McGuire, M.D. currently serves as the chief medical officer of Acologix. Dr. McGuire is a board certified neurologist with more than a decade of executive leadership in drug development. Prior to joining Acologix, Dr. McGuire was the chief medical officer of Pepgen Corporation. Dr. McGuire was also formerly chief medical officer of Avigen, Inc. At Elan Pharmaceuticals, she was vice president of clinical research, where she served as development leader for Tysabri, a drug now marketed for the treatment of patients with relapsing forms of multiple sclerosis (MS). From 1999 to 2002, Dr. McGuire served as chief executive officer of Eunoe, Inc. Dr. McGuire also holds several academic and service positions, including American Academy of Neurology committee memberships, peer review committee membership in the National Institute of Neurological Disorders and Stroke of the National Institutes of Health (NIH), and serves on the Advisory Council of the Gill Heart Institute. Dr. McGuire received her B.A. with high honors from Princeton University and her M.D. from Columbia University, College of Physicians & Surgeons. She was trained in Neurology at the University of California, San Francisco, followed by an NIH-funded postdoctoral fellowship in clinical trial design and experimental therapeutics.
Jingwu Zhang, M.D., Ph.D.
Jingwu Zang, M.D., Ph.D. received his medical degree from the Shanghai Second Medical University (now JiaoTong University School of Medicine) and went on to earn his PhD in Immunology, where he started his illustrious pursuit of a cure for multiple sclerosis and other autoimmune diseases through basic and clinical research. He later received an advanced research fellowship award from the U.S. National Multiple Sclerosis Society and conducted his postdoctoral research on multiple sclerosis at Harvard Medical School. Dr. Zang joined the faculty of Neurology and Immunology at Baylor College of Medicine where he completed a clinical residency program. Prior to his career in Shanghai, he had been Professor of Neurology and Immunology, a U.S. licensed physician and Research Director of the Multiple Sclerosis Center at Baylor College of Medicine in Houston, Texas . Dr. Zang has been a leading neuroimmunologist in the field of multiple sclerosis and has published over 130 scientific articles in chapters, books and such prestigious journals as Science, JEM, JCI, PNAS, Brain, Annals of Neurology, Nature Immunology, etc. He is well known for his pioneering work in T cell vaccination as a treatment for multiple sclerosis, which led to landmark publications in Science. In his recent career Dr. Zang established the Institute of Health Sciences as the founding director with the Chinese Academy of Sciences and JiaoTong University School of Medicine and co-founded the Institut Pasteur Shanghai with the Chinese Academy of Sciences and Institut Pasteur Paris. Institute of Health Sciences, a unique translational research institute, has thrived under his leadership and rapidly become one of top translational research institutions. Recently, Dr. Zang joined GlaxoSmithKline as Senior Vice President, to head GlaxoSmithKline’s global Research and Development Center in Shanghai, China.